Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 362

    1.

    Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors.

    Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fosså SD.

    J Natl Cancer Inst. 2009 Nov 25. [Epub ahead of print]PMID: 19940282 [PubMed - as supplied by publisher]

    2.

    cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy.

    Borkamo ED, Schem BC, Fluge Ø, Bruland O, Dahl O, Mella O.

    Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1562-9.PMID: 19931738 [PubMed - in process]

    3.

    Cost and efficiency lead to increased value for the patient and bottom line for the practice.

    Dahl OJ.

    J Med Pract Manage. 2009 Sep-Oct;25(2):87-9.PMID: 19911540 [PubMed - in process]Related articles

    4.

    Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.

    Christoffersen T, Guren TK, Spindler KL, Dahl O, Lønning PE, Gjertsen BT.

    Eur J Pharmacol. 2009 Dec 25;625(1-3):6-22. Epub 2009 Oct 18.PMID: 19836383 [PubMed - in process]Related articles

    5.

    SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

    Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.

    Nat Genet. 2009 Nov;41(11):1238-42. Epub 2009 Oct 4.PMID: 19801978 [PubMed - in process]Related articles

    6.

    Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.

    Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA, Dahl O; Norwegian Gastrointestinal Cancer Group.

    Br J Cancer. 2009 Oct 20;101(8):1282-9. Epub 2009 Sep 22.PMID: 19773751 [PubMed - indexed for MEDLINE]Related articles

    7.

    Dabigatran Etexilate for the Prophylaxis of Venous Thromboembolism After Hip or Knee Replacement: Rationale for Dose Regimen.

    Dahl OE.

    Clin Appl Thromb Hemost. 2009 Aug 19. [Epub ahead of print]PMID: 19696041 [PubMed - as supplied by publisher]Related articles

    8.

    Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996.

    Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM.

    Int J Hyperthermia. 2009 Aug;25(5):323-34. No abstract available. PMID: 19670088 [PubMed - indexed for MEDLINE]Related articles

    9.

    Topography of solitary congenital hypertrophy of the retinal pigment epithelium in the ocular fundus.

    Krohn J, Frøystein T, Dahl O.

    Acta Ophthalmol. 2009 Jul 14. [Epub ahead of print] No abstract available. PMID: 19604161 [PubMed - as supplied by publisher]Related articles

    10.

    Late Side Effects and Quality of Life After Radiotherapy for Rectal Cancer.

    Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM.

    Int J Radiat Oncol Biol Phys. 2009 Jun 17. [Epub ahead of print]PMID: 19540058 [PubMed - as supplied by publisher]Related articles

    11.

    Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.

    Karlsdottir A, Muren LP, Wentzel-Larsen T, Johannessen DC, Haukaas SA, Halvorsen OJ, Dahl O.

    Acta Oncol. 2009;48(6):874-81.PMID: 19488886 [PubMed - in process]Related articles

    12.

    Pulmonary function in long-term survivors of testicular cancer.

    Haugnes HS, Aass N, Fosså SD, Dahl O, Brydøy M, Aasebø U, Wilsgaard T, Bremnes RM.

    J Clin Oncol. 2009 Jun 10;27(17):2779-86. Epub 2009 May 4.PMID: 19414680 [PubMed - indexed for MEDLINE]Related articles

    13.

    The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors.

    Grov EK, Fosså SD, Bremnes RM, Dahl O, Klepp O, Wist E, Dahl AA.

    Acta Oncol. 2009;48(6):842-9.PMID: 19412812 [PubMed - in process]Related articles

    14.

    Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer.

    Jullumstrø E, Lydersen S, Møller B, Dahl O, Edna TH.

    Eur J Cancer. 2009 Sep;45(13):2383-90. Epub 2009 Apr 6.PMID: 19356923 [PubMed - indexed for MEDLINE]Related articles

    15.

    Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

    Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O.

    J Clin Oncol. 2009 May 1;27(13):2122-8. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3263. PMID: 19307506 [PubMed - indexed for MEDLINE]Related articles

    16.

    Utilisation of specialist care in patients with incurable rectal cancer. a population-based study from Western Norway.

    Sigurdsson HK, Søreide JA, Dahl O, Skarstein A, Von Hofacker S, Kørner H.

    Acta Oncol. 2009;48(3):377-84.PMID: 19294541 [PubMed - indexed for MEDLINE]Related articles

    17.

    Follow up your unexpected clinical observations!

    Dahl O.

    Acta Oncol. 2009;48(3):325-7. No abstract available. PMID: 19294540 [PubMed - indexed for MEDLINE]Related articles

    18.

    Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.

    Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM; Norwegian Gastrointestinal Cancer Group.

    Acta Oncol. 2009;48(3):368-76.PMID: 19242829 [PubMed - indexed for MEDLINE]Related articles

    19.

    Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor.

    Borkamo ED, Dahl O, Bruland O, Fluge Ø.

    Int J Hyperthermia. 2009 Feb;25(1):41-6.PMID: 19219699 [PubMed - indexed for MEDLINE]Related articles

    20.

    AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study.

    Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG.

    J Thromb Haemost. 2009 Apr;7(4):566-72. Epub 2009 Jan 24.PMID: 19187076 [PubMed - indexed for MEDLINE]Related articles

    21.

    Rectal cancer with macroscopic peritoneal involvement--clinical challenges and consequences.

    Sigurdsson HK, Kørner H, Dahl O, Skarstein A, Søreide JA; Norwegian Colorectal Cancer Group.

    Colorectal Dis. 2009 Oct;11(8):838-44. Epub 2008 Oct 1.PMID: 19175632 [PubMed - in process]Related articles

    22.

    Six Sigma and modifications to gain an efficient practice.

    Dahl OJ.

    J Med Pract Manage. 2008 Sep-Oct;24(2):88-90.PMID: 19174966 [PubMed - indexed for MEDLINE]Related articles

    23.

    Who's measuring your group's quality?

    Dahl OJ, Rahman A, Dunnahoe J, Garza R, Grigsby K.

    MGMA Connex. 2008 Nov-Dec;8(10):31-3. No abstract available. PMID: 19160689 [PubMed - indexed for MEDLINE]Related articles

    24.

    Topographical distribution of choroidal naevi in the ocular fundus.

    Krohn J, Frøystein T, Dahl O.

    Eye (Lond). 2009 Aug;23(8):1685-90. Epub 2008 Nov 28.PMID: 19039331 [PubMed - in process]Related articles

    25.

    Fear of recurrence in long-term testicular cancer survivors.

    Skaali T, Fosså SD, Bremnes R, Dahl O, Haaland CF, Hauge ER, Klepp O, Oldenburg J, Wist E, Dahl AA.

    Psychooncology. 2009 Jun;18(6):580-8.PMID: 18855944 [PubMed - indexed for MEDLINE]Related articles

    26.

    Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors.

    Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM.

    J Cancer Surviv. 2008 Sep;2(3):128-37. Epub 2008 May 29.PMID: 18792787 [PubMed - indexed for MEDLINE]Related articles

    27.

    Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.

    Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.

    Thromb Haemost. 2008 Sep;100(3):453-61.PMID: 18766262 [PubMed - indexed for MEDLINE]Related articles

    28.

    2008 ESHO-BSD Award Winner--Gerard C. van Rhoon.

    Dahl O.

    Int J Hyperthermia. 2008 Aug;24(5):444-5. No abstract available. PMID: 18716944 [PubMed - indexed for MEDLINE]Related articles

    29.

    Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy.

    Røe K, Muren LP, Rørvik J, Olsen DR, Dahl O, Bakke A, Malinen E.

    Acta Oncol. 2008;47(7):1257-64.PMID: 18618299 [PubMed - indexed for MEDLINE]Related articles

    30.

    Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model.

    Borkamo ED, Dahl O, Bruland O, Fluge O.

    Int J Hyperthermia. 2008 Aug;24(5):425-41.PMID: 18608572 [PubMed - indexed for MEDLINE]Related articles

    31.

    Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators.

    Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24.PMID: 18582928 [PubMed - indexed for MEDLINE]Related articles

    32.

    Trace elements in serum from patients with Parkinson's disease--a prospective case-control study: the Nord-Trøndelag Health Study (HUNT).

    Gellein K, Syversen T, Steinnes E, Nilsen TI, Dahl OP, Mitrovic S, Duraj D, Flaten TP.

    Brain Res. 2008 Jul 11;1219:111-5. Epub 2008 May 9.PMID: 18538747 [PubMed - indexed for MEDLINE]Related articles

    33.

    Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus.

    Krohn J, Frøystein T, Dahl O.

    Br J Ophthalmol. 2008 Jun;92(6):751-6.PMID: 18523080 [PubMed - indexed for MEDLINE]Related articles

    34.

    Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.

    Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; EXTEND Study Group.

    Thromb Res. 2009;123(3):488-97. Epub 2008 May 15.PMID: 18485453 [PubMed - indexed for MEDLINE]Related articles

    35.

    What does it cost you to see a patient?

    Dahl OJ.

    J Med Pract Manage. 2008 Mar-Apr;23(5):261-5.PMID: 18472597 [PubMed - indexed for MEDLINE]Related articles

    37.

    Chronic cancer-related fatigue in long-term survivors of testicular cancer.

    Orre IJ, Fosså SD, Murison R, Bremnes R, Dahl O, Klepp O, Loge JH, Wist E, Dahl AA.

    J Psychosom Res. 2008 Apr;64(4):363-71.PMID: 18374735 [PubMed - indexed for MEDLINE]Related articles

    38.

    Gene expression reveals two distinct groups of anal carcinomas with clinical implications.

    Bruland O, Fluge O, Immervoll H, Balteskard L, Myklebust M, Skarstein A, Dahl O.

    Br J Cancer. 2008 Apr 8;98(7):1264-73. Epub 2008 Mar 18.PMID: 18349847 [PubMed - indexed for MEDLINE]Related articlesFree article

    39.

    Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.

    Borkamo ED, Fluge O, Mella O, Akslen LA, Bruland O, Dahl O.

    Radiother Oncol. 2008 Mar;86(3):435-42. Epub 2008 Mar 4.PMID: 18313158 [PubMed - indexed for MEDLINE]Related articles

    40.

    Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

    Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG.

    Clin Pharmacokinet. 2008;47(3):203-16.PMID: 18307374 [PubMed - indexed for MEDLINE]Related articles

    41.

    Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.

    Dahl OE, Borris LC, Bergqvist D, Schnack Rasmussen M, Eriksson BI, Kakkar AK, Colwell CW, Caprini JA, Fletcher J, Friedman RJ, Lassen MR, Frostick SP, Sakon M, Kwong LM, Kakkar VV; International Surgical Thrombosis Forum.

    Int Angiol. 2008 Feb;27(1):60-7.PMID: 18277341 [PubMed - indexed for MEDLINE]Related articles

    42.

    Orthopaedic thromboprophylaxis: limitations of current guidelines.

    Warwick D, Dahl OE, Fisher WD; International Surgical Thrombosis Forum.

    J Bone Joint Surg Br. 2008 Feb;90(2):127-32. Review.PMID: 18256075 [PubMed - indexed for MEDLINE]Related articles

    43.

    Current status of antivascular therapy and targeted treatment in the clinic.

    Dahl O, Borkamo ED, Fluge O.

    Int J Hyperthermia. 2008 Feb;24(1):97-110. Review.PMID: 18214773 [PubMed - indexed for MEDLINE]Related articles

    44.

    [Anal cancer]

    Dahl O, Fluge Ø.

    Tidsskr Nor Laegeforen. 2008 Jan 17;128(2):198-200. Review. Norwegian. PMID: 18202733 [PubMed - indexed for MEDLINE]Related articlesFree article

    45.

    Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study.

    Eriksson BI, Dahl OE, Lassen MR, Ward DP, Rothlein R, Davis G, Turpie AG; Fixit Study Group.

    J Thromb Haemost. 2008 Mar;6(3):457-63. Epub 2007 Dec 12.PMID: 18088349 [PubMed - indexed for MEDLINE]Related articles

    46.

    Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.

    Karlsdóttir A, Muren LP, Wentzel-Larsen T, Dahl O.

    Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1478-86. Epub 2007 Dec 3.PMID: 18060703 [PubMed - indexed for MEDLINE]Related articles

    47.

    [Adjuvant chemotherapy for colon cancer]

    Dahl O.

    Tidsskr Nor Laegeforen. 2007 Nov 29;127(23):3094-6. Review. Norwegian. PMID: 18049502 [PubMed - indexed for MEDLINE]Related articlesFree article

    48.

    [Radiotherapy of rectal cancer.]

    Balteskard L, Vonen B, Frykholm G, Dahl O, Tveit KM.

    Tidsskr Nor Laegeforen. 2007 Nov 29;127(23):3090-3. Review. Norwegian. PMID: 18049501 [PubMed - indexed for MEDLINE]Related articlesFree article

    49.

    Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.

    Sørbye H, Berglund A, Tveit KM, Ogreid D, Wanderås EH, Wentzel-Larsen T, Dahl O, Glimelius B.

    Acta Oncol. 2007;46(7):982-8.PMID: 17917829 [PubMed - indexed for MEDLINE]Related articles

    50.

    Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group.

    Lancet. 2007 Sep 15;370(9591):949-56. Erratum in: Lancet. 2007 Dec 15;370(9604):2004. PMID: 17869635 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...